A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

Trial Profile

A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Acronyms M207-ADAM
  • Sponsors Zosano Pharma
  • Most Recent Events

    • 08 Nov 2017 The first patient has been enrolled in this trial. The study will evaluate 150 patients for six months, and 50 patients for a year at approximately 30 sites in the U.S., as reported in a Zosano Pharma media release.
    • 08 Nov 2017 Status changed from planning to recruiting, as reported in a Zosano Pharma media release.
    • 26 Jun 2017 According to a Zosano Pharma media release, the company anticipates initiating this trial in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top